Abstract
Repurposing agents approved for other indications to radiosensitize tumors may be advantageous. The study by Hill and colleagues utilizes nelfinavir, an HIV protease inhibitor (PI), in combination with radiotherapy in rectal cancer in a prospective study. This combination may improve tumor perfusion and regression compared with radiotherapy alone.
©2016 American Association for Cancer Research.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Combined Modality Therapy
-
Humans
-
Magnetic Resonance Imaging
-
Nelfinavir / therapeutic use*
-
Radiation Dose Hypofractionation
-
Radiation-Sensitizing Agents / therapeutic use*
-
Rectal Neoplasms / diagnosis
-
Rectal Neoplasms / drug therapy*
-
Rectal Neoplasms / radiotherapy*
-
Tomography, X-Ray Computed
-
Treatment Outcome
Substances
-
Radiation-Sensitizing Agents
-
Nelfinavir